These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32479952)

  • 41. Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy.
    Wan X; Song M; Wang A; Zhao Y; Wei Z; Lu Y
    Front Immunol; 2021; 12():747914. PubMed ID: 34745119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of the host intestinal microbiome on carcinogenesis and the response to chemotherapy.
    Wertman JN; Dunn KA; Kulkarni K
    Future Oncol; 2021 Nov; 17(32):4371-4387. PubMed ID: 34448411
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review.
    Liu L; Shah K
    JAMA Oncol; 2022 Jul; 8(7):1059-1067. PubMed ID: 35482355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The microbiome and precision oncology: an emerging paradigm in anticancer therapy.
    Bhat SA; Kaur R; Chauhan A; Pal A
    Crit Rev Microbiol; 2022 Nov; 48(6):770-783. PubMed ID: 35164642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.
    Zitvogel L; Ma Y; Raoult D; Kroemer G; Gajewski TF
    Science; 2018 Mar; 359(6382):1366-1370. PubMed ID: 29567708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular and Cellular Mechanisms Influenced by Postbiotics.
    Jastrząb R; Graczyk D; Siedlecki P
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy.
    Zhu R; Lang T; Yan W; Zhu X; Huang X; Yin Q; Li Y
    Adv Sci (Weinh); 2021 May; 8(10):2003542. PubMed ID: 34026439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy-induced gastrointestinal toxicity.
    Secombe KR; Coller JK; Gibson RJ; Wardill HR; Bowen JM
    Int J Cancer; 2019 May; 144(10):2365-2376. PubMed ID: 30155890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microbiome and cancer treatment: Are we ready to apply in clinics?
    Chan SL
    Prog Mol Biol Transl Sci; 2020; 171():301-308. PubMed ID: 32475526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity.
    Baiden-Amissah REM; Tuyaerts S
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31340438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites.
    Malczewski AB; Ketheesan N; Coward JIG; Navarro S
    Front Immunol; 2021; 12():624434. PubMed ID: 34305883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of cancer immunotherapy efficacy by gut microbiota.
    Huo S; Liu L; Liu J; Li Q; Wang J
    Discov Med; 2019 Feb; 27(147):93-100. PubMed ID: 30939293
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microbiota and cancer immunotherapy: in search of microbial signals.
    Gharaibeh RZ; Jobin C
    Gut; 2019 Mar; 68(3):385-388. PubMed ID: 30530851
    [No Abstract]   [Full Text] [Related]  

  • 55. Harnessing the Microbiome for Pancreatic Cancer Immunotherapy.
    Vitiello GA; Cohen DJ; Miller G
    Trends Cancer; 2019 Nov; 5(11):670-676. PubMed ID: 31735286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy.
    Chrysostomou D; Roberts LA; Marchesi JR; Kinross JM
    Gastroenterology; 2023 Feb; 164(2):198-213. PubMed ID: 36309208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The role of intestinal microbiota in the response to anti-tumor therapies].
    Vétizou M; Daillère R; Zitvogel L
    Med Sci (Paris); 2016 Nov; 32(11):974-982. PubMed ID: 28008838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Intestinal microbiom modulates the response to antitumor immunotherapy].
    Olekhnovich EI; Manolov AI; Pavlenko AV; Konanov DN; Fedorov DE; Tikhonova PO; Glushchenko OE; Ilina EN
    Biomed Khim; 2020 Jan; 66(1):54-63. PubMed ID: 32116226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of microbiota, mucosal malignancies, and immunotherapy-Mechanistic insights.
    Mager LF; Krause T; McCoy KD
    Mucosal Immunol; 2024 Jun; 17(3):402-415. PubMed ID: 38521413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome.
    Nguyen NA; Jiang Y; McQuade JL
    Front Immunol; 2024; 15():1409414. PubMed ID: 38873602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.